Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies : A report from the ITA-HEMA-COV
© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd..
The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Hematological oncology - 40(2022), 5 vom: 20. Dez., Seite 846-856 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343747421 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343747421 | ||
| 003 | DE-627 | ||
| 005 | 20231226021153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343747421 | ||
| 035 | |a (NLM)35854643 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zappasodi, Patrizia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies |b A report from the ITA-HEMA-COV |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd. | ||
| 520 | |a The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a hematological malignancies | |
| 650 | 4 | |a outcome | |
| 650 | 4 | |a secondary infections | |
| 700 | 1 | |a Cattaneo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Valeria Ferretti, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Mina, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a José María Ferreri, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Oberti, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Krampera, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbi, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Salvini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bertù, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Stefano Fracchiolla, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Massaia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Marasco, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Cairoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Maria Scattolin, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Maria Vannucchi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Gambacorti-Passerini, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Gherlinzoni, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Cuneo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Trentin, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchia, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Galimberti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Coviello, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Chiara Tisi, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Morotti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Falini, Brunangelo |e verfasserin |4 aut | |
| 700 | 1 | |a Turrini, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Tafuri, Agostino |e verfasserin |4 aut | |
| 700 | 1 | |a Billio, Atto |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Massimo Lemoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Venditti, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Giovanni Della Porta, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Lanza, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Rigacci, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Tosi, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Corso, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Luppi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Busca, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio Grossi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Passamonti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaini, Luca |e verfasserin |4 aut | |
| 700 | 0 | |a ITA-HEMA-COV Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 40(2022), 5 vom: 20. Dez., Seite 846-856 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:5 |g day:20 |g month:12 |g pages:846-856 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 5 |b 20 |c 12 |h 846-856 | ||